专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012096873A9 METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE 审中-公开
标题翻译：用于治疗阿尔茨海默病的方法和药物产品
公开(公告)号：WO2012096873A9
公开(公告)日：2013-09-12
申请号：PCT/US2012020606
申请日：2012-01-09
申请人： ZINFANDEL PHARMACEUTICALS INC , TAKEDA PHARMACEUTICAL , ROSES ALLEN D , TANEJA RAJNEESH
发明人： ROSES ALLEN D , TANEJA RAJNEESH
IPC分类号： A61K31/4436 , C12Q1/68
CPC分类号： A61K31/4439 , C07D417/12 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , Y10T436/143333
摘要： Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
摘要翻译：本文提供了具有低剂量吡格列酮的药物产品，用于治疗（例如，延迟发作）阿尔茨海默型认知障碍。还提供了其制造方法。还提供了治疗阿尔茨海默氏病的方法，包括用低剂量吡格列酮给药药物。该方法可以包括基于受试者的年龄和TOMM40 523基因型确定受试者是否处于发展阿尔茨海默氏病的风险中。

2. 发明申请

WO2003056328A1 HIGH THROUGHPUT CORRELATION OF POLYMORPHIC FORMS WITH MULTIPLE PHENOTYPES WITHIN CLINICAL POPULATIONS 审中-公开
标题翻译：在临床人群中具有多个基因的多态性与高度相关性
公开(公告)号：WO2003056328A1
公开(公告)日：2003-07-10
申请号：PCT/US2002/040358
申请日：2002-12-18
申请人： SMITHKLINE BEECHAM CORPORATION , ROSES, Allen, D.
发明人： ROSES, Allen, D.
IPC分类号： G01N33/48
CPC分类号： G06F19/18 , C07K1/00 , C12Q1/6876 , C12Q2600/156 , G06F19/22
摘要： A computer-assisted method of looking for pharmacologic targets, in which large numbers of persons are enrolled in drugh clinical trials, they are medically examined and documented, tissue samples are taken, the tissue samples are genotyped, and an examination is made of the genotypes to try to ascertain associations between the genotypes and the documented disease phenotypes of the patients.
摘要翻译：寻找药物靶点的计算机辅助方法，其中大量人员参加了drugh临床试验，他们经过医学检查和记录，采集组织样本，组织样本进行基因分型，并检查基因型尝试确定基因型与患者的已记录疾病表型之间的关联。

3. 发明申请

WO2013106084A1 METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE 审中-公开
标题翻译：用于治疗阿尔茨海默病的方法和药物产品
公开(公告)号：WO2013106084A1
公开(公告)日：2013-07-18
申请号：PCT/US2012/046692
申请日：2012-07-13
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , ZINFANDEL PHARMACEUTICALS, INC. , ROSES, Allen, D. , TANEJA, Rajneesh
发明人： ROSES, Allen, D. , TANEJA, Rajneesh
IPC分类号： A61K31/44 , A61P25/28
CPC分类号： A61K47/12 , A61K9/0095 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K31/4439 , A61K47/10 , A61K47/26 , A61K47/38
摘要： Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
摘要翻译：本文提供了用于治疗（例如延迟发作）阿尔茨海默氏型认知障碍的低剂量吡格列酮的药物产品。还提供了其制造方法。还提供了治疗阿尔茨海默病的方法，包括给予低剂量吡格列酮的药物。方法可以包括基于受试者的年龄和TOMM40523基因型来确定受试者是否处于发展阿尔茨海默病的风险中。

4. 发明申请

WO2012096873A1 METHODS AND DRUG PRODUCTS FOR TREATING ALZHEIMER'S DISEASE 审中-公开
标题翻译：用于治疗阿尔茨海默病的方法和药物产品
公开(公告)号：WO2012096873A1
公开(公告)日：2012-07-19
申请号：PCT/US2012/020606
申请日：2012-01-09
申请人： ZINFANDEL PHARMACEUTICALS, INC. , TAKEDA PHARMACEUTICAL COMPANY LIMITED , ROSES, Allen D. , TANEJA, Rajneesh
发明人： ROSES, Allen D. , TANEJA, Rajneesh
IPC分类号： A61K31/4436 , C12Q1/68
CPC分类号： A61K31/4439 , C07D417/12 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , Y10T436/143333
摘要： Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.
摘要翻译：本文提供了用于治疗（例如延迟发作）阿尔茨海默氏型认知障碍的低剂量吡格列酮的药物产品。还提供了其制造方法。还提供了治疗阿尔茨海默病的方法，包括给予低剂量吡格列酮的药物。方法可以包括基于受试者的年龄和TOMM40523基因型来确定受试者是否处于发展阿尔茨海默病的风险中。

5. 发明申请

WO2010019550A4 METHOD OF IDENTIFYING DISEASE RISK FACTORS 审中-公开
标题翻译：鉴别疾病风险因子的方法
公开(公告)号：WO2010019550A4
公开(公告)日：2011-01-13
申请号：PCT/US2009053373
申请日：2009-08-11
申请人： SHIRAZ PHARMACEUTICALS INC , ROSES ALLEN D
发明人： ROSES ALLEN D
IPC分类号： G01N33/48 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.
摘要翻译：本文提供了用于鉴定与兴趣条件（例如阿尔茨海默病）的发展相关的遗传变异体和如此鉴定的遗传变异体的方法。在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。还提供了用于确定受试者是否处于发病晚期阿尔茨海默氏病的风险增加的试剂盒。进一步提供用于确定受试者是否对活性成分感兴趣的病症的治疗有反应的试剂盒。

6. 发明申请

WO2007038115A2 METHOD OF IMPROVEMENT OF COGNITIVE FUNCTION 审中-公开
标题翻译：改进认知功能的方法
公开(公告)号：WO2007038115A2
公开(公告)日：2007-04-05
申请号：PCT/US2006/036603
申请日：2006-09-20
申请人： SB PHARMCO PUERTO RICO INC. , ROSES, Allen, D. , SAUNDERS, Ann, M.
发明人： ROSES, Allen, D. , SAUNDERS, Ann, M.
CPC分类号： A61K9/5084 , A61K9/2072 , A61K9/209 , A61K9/2846 , A61K9/2886 , A61K9/5078 , A61K31/4439 , A61K31/445 , G01N33/92 , G01N2800/2814 , G01N2800/2821 , A61K2300/00
摘要： A method for improving cognitive function in a subject suffering from or susceptible to MCI, Alzheimer's disease or other dementias, which subject is not homozygous for the APOE4 allele, comprising the steps of: (i) screening the subject to determine that the subject is not homozygous for the APOE4 allele; and then (ii) administering a safe and effective amount of a PPAR-gamma agonist to said subject.
摘要翻译：一种改善MCI，阿尔茨海默氏病或其他痴呆症患者或易感患者的认知功能的方法，该受试者对于APOE4等位基因不是纯合的，其包括以下步骤：（i）筛选受试者以确定受试者不是 APOE4等位基因纯合子; 然后（ii）向所述受试者施用安全有效量的PPAR-γ激动剂。

7. 发明申请

WO1994009155A1 METHODS OF DETECTING ALZHEIMER'S DISEASE 审中-公开
标题翻译：检测阿尔茨海默病的方法
公开(公告)号：WO1994009155A1
公开(公告)日：1994-04-28
申请号：PCT/US1993009310
申请日：1993-09-30
申请人： DUKE UNIVERSITY , ROSES, Allen, D. , STRITTMATTER, Warren, J. , SALVESEN, Guy, S. , ENGHILD, Jan , SCHMECHEL, Donald, E.
发明人： DUKE UNIVERSITY
IPC分类号： C12Q01/68
CPC分类号： C07K14/755 , C07K14/775 , C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172 , Y10S435/81
摘要： Methods of diagnosing or prognosing Alzheimer's disease in a subject are disclosed. The method involves detecting the presence or absence of an apolipoprotein E type 4 (ApoE4) isoform or DNA encoding ApoE4 in the subject. The presence of ApoE4 indicates the subject is afflicted with Alzheimer's disease or at risk of developing Alzheimer's disease.
摘要翻译：公开了在受试者中诊断或预测阿尔茨海默氏病的方法。该方法涉及检测受试者中载脂蛋白E型4型（ApoE4）同种型或编码ApoE4的DNA的存在或不存在。 ApoE4的存在表明受试者患有阿尔茨海默氏病或患阿尔茨海默氏病的风险。

8. 发明申请

WO2010019550A3 METHOD OF IDENTIFYING DISEASE RISK FACTORS 审中-公开
标题翻译：鉴别疾病风险因子的方法
公开(公告)号：WO2010019550A3
公开(公告)日：2010-04-22
申请号：PCT/US2009053373
申请日：2009-08-11
申请人： SHIRAZ PHARMACEUTICALS INC , ROSES ALLEN D
发明人： ROSES ALLEN D
IPC分类号： G01N33/48 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.
摘要翻译：本文提供了用于鉴定与兴趣条件（例如阿尔茨海默病）的发展相关的遗传变异体和如此鉴定的遗传变异体的方法。在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。还提供了用于确定受试者是否处于发病晚期阿尔茨海默氏病的风险增加的试剂盒。进一步提供用于确定受试者是否对活性成分感兴趣的病症的治疗有反应的试剂盒。

9. 发明申请

WO2012096680A1 DISEASE RISK FACTORS AND METHODS OF USE 审中-公开
标题翻译：疾病风险因素及使用方法
公开(公告)号：WO2012096680A1
公开(公告)日：2012-07-19
申请号：PCT/US2011/025241
申请日：2011-02-17
申请人： ZINFANDEL PHARMACEUTICALS, INC. , ROSES, Allen, D.
发明人： ROSES, Allen, D.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/44 , C12Q2600/156
摘要： Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.
摘要翻译：本文提供与感兴趣的疾病的发展相关的遗传变异（例如，阿尔茨海默病）。在检测本文所述的遗传变体时，还提供了用活性剂（例如，与特定活性剂和/或较早年龄）一起治疗的方法。在一些实施方案中，遗传变体是TOMM40基因的缺失/插入多态性（DIP）。

10. 发明申请

WO2007038115A3 PPAR-GAMMA AGONISTS FOR IMPROVEMENT OF COGNITIVE FUNCTION IN APOE4 NEGATIVE PATIENTS 审中-公开
标题翻译：用于改善APOE4负面患者的认知功能的PPAR-GAMMA AGONISTS
公开(公告)号：WO2007038115A3
公开(公告)日：2007-12-13
申请号：PCT/US2006036603
申请日：2006-09-20
申请人： SB PHARMCO INC , ROSES ALLEN D , SAUNDERS ANN M
发明人： ROSES ALLEN D , SAUNDERS ANN M
IPC分类号： A61K31/4439 , A61K31/445 , A61P25/28
CPC分类号： A61K9/5084 , A61K9/2072 , A61K9/209 , A61K9/2846 , A61K9/2886 , A61K9/5078 , A61K31/4439 , A61K31/445 , G01N33/92 , G01N2800/2814 , G01N2800/2821 , A61K2300/00
摘要： A method for improving cognitive function in a subject suffering from or susceptible to MCI, Alzheimer's disease or other dementias, which subject is not homozygous for the APOE4 allele, comprising the steps of: (i) screening the subject to determine that the subject is not homozygous for the APOE4 allele; and then (ii) administering a safe and effective amount of a PPAR-gamma agonist to said subject.
摘要翻译：一种改善MCI，阿尔茨海默氏病或其他痴呆症患者或易感患者的认知功能的方法，该受试者对于APOE4等位基因不是纯合的，其包括以下步骤：（i）筛选受试者以确定受试者不是 APOE4等位基因纯合子; 然后（ii）向所述受试者施用安全有效量的PPAR-γ激动剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式